Zacks: Analysts Anticipate Aphria Inc (NYSE:APHA) Will Post Earnings of -$0.01 Per Share

Brokerages expect Aphria Inc (NYSE:APHA) to report earnings per share (EPS) of ($0.01) for the current fiscal quarter, Zacks reports. Three analysts have provided estimates for Aphria’s earnings, with the lowest EPS estimate coming in at ($0.03) and the highest estimate coming in at $0.00. Aphria also reported earnings of ($0.01) per share in the same quarter last year. The company is expected to issue its next quarterly earnings report on Friday, January 10th.

According to Zacks, analysts expect that Aphria will report full year earnings of $0.06 per share for the current fiscal year, with EPS estimates ranging from ($0.05) to $0.18. For the next year, analysts forecast that the business will report earnings of $0.21 per share, with EPS estimates ranging from $0.05 to $0.30. Zacks’ EPS averages are an average based on a survey of sell-side analysts that follow Aphria.

Aphria (NYSE:APHA) last announced its earnings results on Tuesday, October 15th. The company reported $0.07 earnings per share for the quarter, topping the consensus estimate of ($0.03) by $0.10. The business had revenue of $126.10 million for the quarter, compared to analyst estimates of $131.15 million. The company’s revenue for the quarter was up 848.1% compared to the same quarter last year.

Several research firms recently issued reports on APHA. CIBC reissued a “sell” rating and set a $6.50 price target on shares of Aphria in a report on Wednesday, October 16th. Cantor Fitzgerald began coverage on shares of Aphria in a report on Tuesday, November 5th. They set an “overweight” rating and a $10.40 price target for the company. Jefferies Financial Group set a $8.30 price target on shares of Aphria and gave the stock a “buy” rating in a report on Tuesday, October 15th. Zacks Investment Research cut shares of Aphria from a “buy” rating to a “hold” rating in a report on Wednesday, November 13th. Finally, Pi Financial set a $9.00 price target on shares of Aphria and gave the stock a “buy” rating in a report on Tuesday, October 15th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and eight have given a buy rating to the stock. The company presently has a consensus rating of “Buy” and a consensus target price of $11.38.

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Synovus Financial Corp increased its holdings in Aphria by 56.9% in the second quarter. Synovus Financial Corp now owns 5,514 shares of the company’s stock valued at $39,000 after buying an additional 2,000 shares in the last quarter. Capital Investment Advisory Services LLC increased its holdings in Aphria by 2,233.3% in the second quarter. Capital Investment Advisory Services LLC now owns 7,000 shares of the company’s stock valued at $43,000 after buying an additional 6,700 shares in the last quarter. Liberty Wealth Management LLC purchased a new position in Aphria in the second quarter valued at about $44,000. Tower Research Capital LLC TRC increased its holdings in Aphria by 76.0% in the second quarter. Tower Research Capital LLC TRC now owns 6,248 shares of the company’s stock valued at $44,000 after buying an additional 2,698 shares in the last quarter. Finally, Lindbrook Capital LLC purchased a new position in Aphria in the second quarter valued at about $53,000. 9.89% of the stock is owned by hedge funds and other institutional investors.

Shares of APHA traded down $0.07 during mid-day trading on Wednesday, hitting $4.67. 2,770,158 shares of the company’s stock were exchanged, compared to its average volume of 5,297,962. Aphria has a fifty-two week low of $3.75 and a fifty-two week high of $10.95. The firm has a market capitalization of $1.19 billion, a P/E ratio of -42.45 and a beta of 2.75. The business’s 50 day moving average is $4.84 and its two-hundred day moving average is $6.03.

Aphria Company Profile

Aphria Inc produces and sells medical cannabis in Canada and internationally. The company offers sativa, indica, and hybrid medical marijuana products, as well as cannabis oils. It serves patients and health professionals. The company also sells its products online. Aphria Inc is headquartered in Leamington, Canada.

Read More: Using other technical indicators with support levels

Get a free copy of the Zacks research report on Aphria (APHA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Aphria (NYSE:APHA)

Receive News & Ratings for Aphria Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aphria and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit